remedial ii renal insufficiency following contrast media administration ii trial renalguard system...
TRANSCRIPT
REMEDIAL II REnal Insufficiency Following Contrast MEDIA
Administration II TriaL RenalGuard system in high risk patients for contrast
induced acute kidney injury
Carlo Briguori, MD, PhDLaboratoy of Interventional Cardiology
Clinica Mediterranea, Naples - Italy
I, Carlo Briguori DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.
Disclosure Statement of Financial Interest
Background
Contrast-induced acute kidney injury (CI-AKI) is a powerful predictor of unfavorable early and late outcome1-3
Several studies showed the advantages of the prophylaxis by sodium bicarbonate solution 4-5
N-acetylcysteine (NAC) 6-7
However, in high risk patients the rate of CI-AKI is still high
1. McCullough PA. J Am Coll Cardiol 2008;51:1419-282. Solomon R. et al. Clin J Am Soc Nephrol 2009;4:1162-11693. Briguori C, et al. Circulation 2010;121:2117-2122.4. Merten GJ et al. JAMA 2004;291:2328-23345. Briguori C, et al. Circulation 2007;115:1211-1217.6. Tepel M et al. N Engl J Med 2000;343:180-184.7. Trivedi H, et al. Am J Med 2009;122:874 e9-15
High risk patientsHypotension 5
IABP 5
CHF 5
Age > 75 years 4
Anemia 3
Diabetes 3
Contrast media volume 1 for each 100 cc3
Serum creatinine >1.5 mg/dl
OR
eGFR <60 mlmin1.73 m2
4
2 for 40-60
4 for 20-60
6 for <20
Risk
Score
Risk of CIAKI
Risk of
Dialysis
5 7.5% 0.04%
6 to 10 14% 0.12%
11 to 16
26.1% 1.09%
16 57.3% 12.6%
Mehran R et al J Am Coll CardiolJ Am Coll Cardiol 2004; 44:1393-9
Background
Creating and maintaining a high urine output is beneficial to prevent kidney damage. This high urine flow rate, indeed, should allow the body to rapidly eliminate contrast, reducing its toxic effects.
Data from the PRINCE study indicate that increasing the urine flow rate (≥150 ml/h) reduces the toxic effect of contrast media 1
A forced diuresis regime is usually achieved by high dose of furosemide which may be deleterious, potentially due to a negative fluid balance 2,3
1. Stevens MA et al. J Am Coll Cardiol 1999;33:403-4112. Weinstein JM et al. Nephron 1992;62:413-4153. Solomon R, et al. N Engl J Med 1994;331:1416-1420.
Background
RenalGuard system
RenalGuard System
RenalGuard Systemclosed loop fluid management system high volume fluid pump high accuracy dual weight measuring systemsingle use intravenous set; urine collection system that interfaces with a standard Foley catheterreal-time display of urine and hydration fluid volumeuser set net fluid gain and fluid bolus administration for patients that require re-hydration prior to and during the procedureautomatic battery back-upautomatic priming of infusion settimely alerts to drain urine bag or to replace the hydration fluid bag.
Purpose
We performed a prospective, randomized study comparing the prophylactic effectiveness of 2 different strategies for preventing CI-AKI:Sodium Bicarbonate plus N-Acetylcysteine
(Control Group) Hydration with RenalGuard system
(RenalGuard Group)
REMEDIAL II• DESIGN: Prospective, randomized, double-arm,
multicenters clinical study
Elective contrast media administration in patients at high risk for CI-AKI(risk score ≥11 and/or eGFR≤30 ml/min/1.73 m2)
RenalGuard group
Control group
CI-AKI(sCr ≥0.3 mg/dL at 48 h)
• Hypothesis:— Reduction in the primary endpoint from 25% in the Control group to
10% in the RenalGuard group
• Sample size:– A total of 266 patients (133 each group) will be necessary to gave the
study 90% power and a significance level <0.05
Sample size
Inclusion criteria
Age 18 y Chronic kidney disease High risk for CI-AKI:
eGFR ≤30 ml/min/1.73 m2 and/or Mehran score ≥ 11
Exclusion criteria
• Primary or rescue PCI Pregnancy Recent (≤ 7 days) contrast media exposure Chronic dialysis and/or history or previous dialysis multiple myeloma pulmonary edema acute myocardial infarction Administration of theophylline, dopamine, mannitol, or fenoldopam or sodium
bicarbonate.
RenalGuard groupRenalGuard group
REMEDIAL II trial
Hydration with normal saline Hydration with normal saline (urine flow (urine flow ≥ 300 ml/h≥ 300 ml/h))
&&NAC (1.5 g/L)NAC (1.5 g/L)
&&limited (0.25 mg/kg) furosemide doselimited (0.25 mg/kg) furosemide dose
Hydration by sodium bicarbonateHydration by sodium bicarbonate(3 ml/Kg i.v. 1 h before (3 ml/Kg i.v. 1 h before
and 1 ml/kg for 6 h after)and 1 ml/kg for 6 h after)&&
NAC 1200 mg BID x 2 & NAC 1200 mg BID x 2 & 1.5 g e.v. during the procedure1.5 g e.v. during the procedure
Sodium Bicardonate &Sodium Bicardonate &AcetylcysteineAcetylcysteine
Uri
ne
flow
rat
e (m
l/h
)
0
100
200
300
400
500
600
0 30 60 90 120 150 180 210 240 270 300 330 360 400
Fole
y Ca
thet
er
Rena
lGua
rd s
yste
mPr
ime
(≤25
0 m
L)
Furo
sem
ide
(0.2
5 m
g/kg
)
Pre-procedure Procedure Post- procedure
Patient ready forprocedure when urine flow rateis ≥300 ml/h
Continuous real-time matched replacement fluid
Time (minutes)
Biomarkers:sCr = baseline, 2, 6, 12, 24 and 48 hourssCyC = baseline, 2, 6, 12, 24 and 48 hoursNGAL = baseline, 2, 6, 12, 24 and 48 hours
RenalGuard group
RenalGuard System
• Primary endpoint:– Rate of CI-AKI, defined as a serum creatinine (sCr) increase 0.3
mg/dLat 48 hours• Secondary endpoints:
– an increase in the sCr concentration 25% and 0.5 mg/dl at 48 hours after contrast exposure
– changes in the serum cystatin C (sCyC) concentration at 24 and 48 hours after contrast exposure
– the rate of acute renal failure requiring dialysis– the rate of in-hospital, and 1 month major adverse events
(MAE), including a) death, b) renal failure requiring dialysis, and c) acute pulmonary edema
– changes in the serum and urine NGAL concentrations at 2, 6, 12, 24 and 48 hours after contrast exposure
Endpoints
Assessed for eligibility ( n= 806)
Exclusion (n = 512)Not meeting inclusion/exclusion criteria (n = 485 )
Refused to partecipate (n = 27)
Randomized (n = 294)
Patients lost at follow-up (n = 0) Discontinued treatment (n = 2)
Patients allocated in the RenalGuard group (n = 147)
Received allocated treatment (n = 146)Did not receive the allocated treatment (n =1)
Patients allocated in the Control group (n = 147)Received allocated treatment (n = 146)Did not receive the allocated treatment (n= 1)
Patients analized ( n = 146) Patients excluded from analysis (n = 0)
Patients lost at follow-up (n = 0) Discontinued treatement (n = 0)
Patients analized ( n = 146) Patients excluded from analysis (n = 0)
Enro
llem
ent
Allo
catio
nFo
llow
-up
Anal
ysis
Clinical CharacteristicsControl Group
(N=146)
RenalGuard Group(N=146)
P
Age, yrs (mean SD) 75 9 76 8 0.31
Male, % 103 (70.5%) 88 (60.5%) 0.065
BMI (kg/m2) 29 5 28 5 0.16
Blood pressure (mm Hg) Systolic Diastolic Mean
152±2778±10
103±13
152±2777±13
102±15
0.99 0.76 0.85
LVEF, % (mean SD) 48 10 46 11 0.10LVEDP (mm Hg) 14±7 14±7 0.81Diabetes mellitus 104 (71%) 101 (69%) 0.51Hypertension, % 144 (98%) 143 (98%) 0.95Drugs: ACE inhibitor Calcium channel blocker Angiotensin II receptor inhibitor Diuretics blocker Statins
67 (46%)44 (30%)45 (31%)85 (58%)88 (60%)
111 (76%)
70 (48%)36 (25%)42 (29%)93 (64%)92 (63%)
108 (74%)
0.770.370.770.360.660.73
Biochemical CharacteristicsControl Group
(N=146)
RenalGuard Group(N=146)
P
eGFR (ml/min/1.73 m2) GFR ≤ 30
32 762 (44%)
32 969 (48.5%)
0.830.41
Serum Urea Nitrogen (mg/dL) Baseline after 48 h
78 3170 ± 30
80 3571±35
0.570.84
Serum Sodium (mEq(L) Baseline after 48 h
140 5139± 6
140 3140 ± 5
0.370.87
Serum Potassium (mEq/L) Baseline after 48 h
4.7 0.74.3 ± 0.6
4.6 0.74.2 ± 0.6
0.550.17
Procedural Characteristics
Control Group
(N=146)
RenalGuard Group(N=146)
P
Performed procedure coronary angiography PCI coronary angiography & PCI peripheral procedure
60 (41%)58 (40%)17 (11%)11 (6%)
51 (35%)71 (49%)11 (7.5%)13 (9%)
0.36
Volume of contrast media (ml) Contrast ratio >1
145 7935 (24%)
135 7628 (19%)
0.290.32
13%
72.5%
12.5%0
20
40
60
80
100
120
Risk score
≥5 ≥6-10 ≥11-15 ≥16
2%
Num
ber o
f pati
ents
Distribution of the Risk score
p <0.001
0
500
1000
1500
2000
2500
3000
Control Group RenalGuard group
Urine Volume at 24 hours
Uri
ne
flow
rat
e (m
l/h
)
0
100
200
300
400
500
600
0 30 60 90 120 150 180 210 240 270 300 330 360 400
Fole
y Ca
thet
er
Rena
lGua
rd s
yste
mPr
ime
(223
±45
mL;
rang
e =
50-3
00)
Furo
sem
ide
(14±
8mg;
rang
e =
0-50
)
Pre-procedure Procedure Post- procedure
Time to reach Target urine flow rate58±19 min (30-120)
Continuous real-time matched replacement fluid
Time (minutes)
Biomarkers:sCr = baseline, 2, 6, 12, 24 and 48 hourssCyC = baseline, 2, 6, 12, 24 and 48 hoursNGAL = baseline, 2, 6, 12, 24 and 48 hours
RenalGuard group
7 h & 54 minutes (4.7-11.5 h)
RenalGuard Group
Time (minutes)
15 45 75 105 135 165 195 225 255 285 315 345 375
Vo
lum
e (
ml)
0
500
1000
1500
2000
2500
3000
3500
4000
infusion
urine
RenalGuard Group
0
100
200
300
400
500
600
700
800
900
15 45 75 105 135 165 195 225 255 285 315 345 375
Time (minutes)
Uri
ne
flo
w r
ate
(m
l/h
)
Mean urine flow rate:352±131 ml/h
Target reached in 93% of patients (416±19 ml/h)
Below the target in 7% of patients (117±48 ml/h)
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
Baseline 24 48
Time (hours)
seru
m c
reati
nine
(med
ian)
p = 0.008; F = 4.97
Control group
RenalGuard group
sCr kinetic
0
5
10
15
20
25
Control group RenalGuard group
CI-A
KI (%
)
30/146
16/146
Odds ratio = 0.47; 95% CI= 0.24-0.92 p = 0.025
Primary endpoint
20.5%
11%
Control group (n= 146)
RenalGuard group (n= 146)
P
Changes in creatinine at 48 hours
Increase ≥0.3 mg/dL Increase ≥0.5 mg/dL Increase ≥25% Increase ≥50%
30 (20.7%) 22 (15%) 19 (13%)
11 (7.5%)
16 (11%) 9 (6%)
4 (2.7%) 1 (0.7%)
0.0250.003 0.001 0.003
Changes in cystatin C at 24 hours*
Increase ≥0.3 mg/dL Increase ≥10% Increase ≥15% Increase ≥25%
21 (15.5%) 33 (24%) 23 (17%) 14 (10%)
11 (8.5%) 22 (16%) 17 (12%) 5 (3.5%)
0.07 0.13 0.29 0.04
Changes in cystatin C a 48 hours*
Increase ≥0.3 mg/dL 29 (21%) 16 (12%) 0.045 Increase ≥10% 47 (34%) 29 (22%) 0.027 Increase ≥15% 35 (25.5%) 21 (16%) 0.050 Increase ≥25% 23 (17%) 11 (8.5%) 0.039
Secondary endpoints
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
Time (hours)
seru
m c
ysta
tin C
(med
ian)
Baseline 24 48
Control group
RenalGuard groupp = 0.004; F = 5.52
sCyC kinetic
Secondary endpointEvents rate at 1-month
0123456789
10
Dialysis DeathPulmonary Edema
Cumulative
%
p = 0.031
p = 0.62
p = 1.0
p = 0.52
4.8
0.7 0.7
2.1
4.1 4.1
9.6
6.8
Control Group
RenalGuard Group
Conclusions
The RenalGuard therapy, including hydration with normal saline plus high dose of NAC controlled by the RenalGuard system in combination with limited (0.25 mg/kg) dose of furosemide, is an effective renoprotective strategy for patients at high- risk for CI-AKI.
REMEDIAL II Investigators• Clinica Mediterranea, Naples
– C. Briguori (P.I.)– A. Focaccio – G. Visconti– B. Golia
• Multimedica IRCCS, Milan– F. Airoldi – D. Tavano– S. Di Biase– S. Bertoli
• University of Ferrara, Ferrara– M. Valgimigli– R. Ferrari
• University of Modena, Modena– G.M. Sangiorgi– M. G. Modena